The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
September 9th 2025
This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.
September 8th 2025
Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib
January 7th 2018A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.
Read More
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 7th 2018The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Watch
This Week in Managed Care: January 5, 2018
January 5th 2018This week, the top managed care stories included an analysis of how healthcare spending has changed in the United States; a study finds people willing to try e-cigarettes smoke less and are more likely to quit; and a new cholesterol test that doesn't require fasting gives more accurate results.
Watch
Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib
January 4th 2018Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.
Read More
Study Shows the Efficacy of Vaccination in Patients With COPD
January 3rd 2018Patients with chronic obstructive pulmonary disease should be given the pneumococcal conjugate vaccine and influenza vaccines to decrease the risk of exacerbations. However, despite the evidence of vaccine efficacy, improvements are needed in coverage and awareness.
Read More
What We're Reading: ACA Repeal Misconception; ACA Enrollment Status; Zika Vaccine Trial
December 28th 2017Poll finds one-third of Americans believe the Affordable Care Act has been repealed; enrollees in Obamacare coverage largely come from states that voted for President Donald Trump; 2 trials find Zika vaccines are safe and effective.
Read More
Checkpoint Inhibitors Associated With Prolonged Survival in NSCLC
December 28th 2017Checkpoint inhibitors, compared with docetaxel, are associated with significantly prolonged overall survival in second and later lines of treatment for advanced non–small cell lung cancer, according to study findings published in JAMA Oncology.
Read More
Can Technology-Based Interventions Be Used to Improve Adherence Among Adolescents?
December 27th 2017Low medication adherence is a problem in healthcare, in general. However, adolescents with chronic health conditions also have low adherence, but they are at a critical age when they can create routines and health behaviors that optimize disease management as they become adults.
Read More
Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation
December 27th 2017Community oncologists have a major role in accelerating treatment development and providing them to patients, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Watch
What We're Reading: TV Drug Ads; Kmart Drug Settlement; Evidence-Based Medicine
December 27th 2017In the last 4 years, the number of drug ads seen on TV has increased 65%; Kmart settled a prescription drug case over allegations it was being overpaid by the government; understanding the term "evidence-based" and how critics and supporters view it.
Read More